FDA Medical Device Classification: Class I, II & III

FDA medical device classification: Class I, II and III

The US FDA assigns device types to three regulatory classes according to the controls needed to provide reasonable assurance of safety and effectiveness. The same framework includes IVDs, but the assay’s analyte, specimen, population and intended use can change the result. A CE class, a competitor’s marketing claim or the word “noninvasive” does not establish an FDA class.

Examples are not classifications for an individual product. Read FDA’s classification explanation, the actual regulation and relevant guidance. Class I does not mean “unregulated,” and a novel device without a predicate is not necessarily high risk.

Product-code lookup: a reproducible workflow

1. Define intended use and indications for use: clinical purpose, patient population, operator, setting and key technology. For IVDs, add specimen, analyte and whether the result drives a critical treatment decision.
2. Search the FDA Product Classification Database using the device’s generic name and relevant medical specialty.
3. Read the regulation number, class, submission type, exemption limitations, special controls and recognized-standard references. Record the rationale and any competing product codes.
4. Examine legally marketed devices in the 510(k) database, De Novo database or PMA database as appropriate. Review actual decision summaries and labeling, not just product names.
5. Compare your claims and technology against those records. Explain differences and the evidence needed to answer any new safety or effectiveness questions.
6. Resolve uncertainty before finalizing testing. A 513(g) request provides FDA information on classification and requirements; a Pre-Submission can address focused evidence questions. Neither grants permission to market.

The three-letter medical-device classification code is different from the longer product code used in FDA import-entry systems. An import Product Code Builder result does not independently determine the premarket pathway.

Classification and marketing pathways are related decisions

A 510(k) relies on substantial equivalence to an eligible legally marketed predicate. Sharing a product code alone does not establish equivalence: intended use, technology and supporting performance evidence matter. A low- or moderate-risk novel device without a suitable predicate may qualify for De Novo classification. General controls, with special controls where needed, must adequately address its risks. A high-risk device may require PMA.

If FDA returns a not-substantially-equivalent decision, investigate the reason before choosing a new route. A missing test report, an unsuitable predicate and a genuinely new device type call for different next steps. Do not treat every NSE decision as an automatic De Novo eligibility decision.

Evidence and exemptions to document

Maintain a classification memo identifying the product boundary, accessories, software functions, regulation, product codes, pathway and sources. Record whether the exemption is limited by intended use or technology. An accessory can have a separate classification; a multi-function product can involve more than one code. Combination-product jurisdiction may require a separate assessment.

Use that memo to plan eSTAR preparation, labeling and tests such as electrical safety, biocompatibility, software verification, cybersecurity and clinical performance where applicable. Changes in claims, patient group, use setting or design can invalidate the original rationale.

After classification, address the separate obligations for registration and listing, QMSR, UDI and postmarket reporting. Pure Global can turn the classification rationale into an evidence and submission plan with defined responsibilities and unresolved questions.

Use the Class I, II and III comparison guide for additional worked classification context.